Tag - Tim Lugo

Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024

Markets

WB starts Brickell Biotech at OP; fair value estimate $2

William Blair initiated coverage of Brickell Biotech (NASDAQ:BBI) with an “outperform” rating and fair value estimate of $2. The stock closed at 21 cents on March 7. Brickell is a biopharmaceutical company focused on...

March 8, 2022

Markets

WB ups VistaGen Therapeutics to OP; fair value estimate $9

William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...

January 4, 2021

Markets

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

William Blair downgraded VistaGen Therapeutics (NASDAQ:VTGN) to “market perform” after the Phase 2 ELEVATE study of AV-101 for the adjunctive treatment of major depressive disorder (MDD) failed to meet its primary...

November 14, 2019

Markets

WB starts VistaGen Therapeutics at OP; fair value estimate $7

William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing...

August 28, 2019

Tag - Tim Lugo

William Blair starts Solid Biosciences at OP

WB starts Brickell Biotech at OP; fair value estimate $2

WB ups VistaGen Therapeutics to OP; fair value estimate $9

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

General

More